Cargando…
The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus
BACKGROUND: Individual clinical trials and cohort studies are a useful source of data, often under-utilised once a study has ended. Pooling data from multiple sources could increase sample sizes and allow for further investigation of treatment effects; even if the original trial did not meet its pri...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313210/ https://www.ncbi.nlm.nih.gov/pubmed/32580708 http://dx.doi.org/10.1186/s12874-020-01057-0 |
_version_ | 1783549905113972736 |
---|---|
author | Le Sueur, Helen Bruce, Ian N. Geifman, Nophar |
author_facet | Le Sueur, Helen Bruce, Ian N. Geifman, Nophar |
author_sort | Le Sueur, Helen |
collection | PubMed |
description | BACKGROUND: Individual clinical trials and cohort studies are a useful source of data, often under-utilised once a study has ended. Pooling data from multiple sources could increase sample sizes and allow for further investigation of treatment effects; even if the original trial did not meet its primary goals. Through the MASTERPLANS (MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches) national consortium, focused on Systemic Lupus Erythematosus (SLE), we have gained valuable real-world experiences in aligning, harmonising and combining data from multiple studies and trials, specifically where standards for data capture, representation and documentation, were not used or were unavailable. This was not without challenges arising both from the inherent complexity of the disease and from differences in the way data were captured and represented across different studies. MAIN BODY: Data were, unavoidably, aligned by hand, matching up equivalent or similar patient variables across the different studies. Heterogeneity-related issues were tackled and data were cleaned, organised and combined, resulting in a single large dataset ready for analysis. Overcoming these hurdles, often seen in large-scale data harmonization and integration endeavours of legacy datasets, was made possible within a realistic timescale and limited resource by focusing on specific research questions driven by the aims of MASTERPLANS. Here we describe our experiences tackling the complexities in the integration of large, diverse datasets, and the lessons learned. CONCLUSIONS: Harmonising data across studies can be complex, and time and resource consuming. The work carried out here highlights the importance of using standards for data capture, recording, and representation, to facilitate both the integration of large datasets and comparison between studies. Where standards are not implemented at the source harmonisation is still possible by taking a flexible approach, with systematic preparation, and a focus on specific research questions. |
format | Online Article Text |
id | pubmed-7313210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73132102020-06-24 The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus Le Sueur, Helen Bruce, Ian N. Geifman, Nophar BMC Med Res Methodol Debate BACKGROUND: Individual clinical trials and cohort studies are a useful source of data, often under-utilised once a study has ended. Pooling data from multiple sources could increase sample sizes and allow for further investigation of treatment effects; even if the original trial did not meet its primary goals. Through the MASTERPLANS (MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches) national consortium, focused on Systemic Lupus Erythematosus (SLE), we have gained valuable real-world experiences in aligning, harmonising and combining data from multiple studies and trials, specifically where standards for data capture, representation and documentation, were not used or were unavailable. This was not without challenges arising both from the inherent complexity of the disease and from differences in the way data were captured and represented across different studies. MAIN BODY: Data were, unavoidably, aligned by hand, matching up equivalent or similar patient variables across the different studies. Heterogeneity-related issues were tackled and data were cleaned, organised and combined, resulting in a single large dataset ready for analysis. Overcoming these hurdles, often seen in large-scale data harmonization and integration endeavours of legacy datasets, was made possible within a realistic timescale and limited resource by focusing on specific research questions driven by the aims of MASTERPLANS. Here we describe our experiences tackling the complexities in the integration of large, diverse datasets, and the lessons learned. CONCLUSIONS: Harmonising data across studies can be complex, and time and resource consuming. The work carried out here highlights the importance of using standards for data capture, recording, and representation, to facilitate both the integration of large datasets and comparison between studies. Where standards are not implemented at the source harmonisation is still possible by taking a flexible approach, with systematic preparation, and a focus on specific research questions. BioMed Central 2020-06-24 /pmc/articles/PMC7313210/ /pubmed/32580708 http://dx.doi.org/10.1186/s12874-020-01057-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Debate Le Sueur, Helen Bruce, Ian N. Geifman, Nophar The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus |
title | The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus |
title_full | The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus |
title_fullStr | The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus |
title_full_unstemmed | The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus |
title_short | The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus |
title_sort | challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of systemic lupus erythematosus |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313210/ https://www.ncbi.nlm.nih.gov/pubmed/32580708 http://dx.doi.org/10.1186/s12874-020-01057-0 |
work_keys_str_mv | AT lesueurhelen thechallengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus AT bruceiann thechallengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus AT geifmannophar thechallengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus AT thechallengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus AT lesueurhelen challengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus AT bruceiann challengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus AT geifmannophar challengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus AT challengesindataintegrationheterogeneityandcomplexityinclinicaltrialsandpatientregistriesofsystemiclupuserythematosus |